PD 163070, a potent endothelin-A selective antagonist with long duration of action.

被引：0

作者：

Lee, C ^{[1
]}

Cheng, XM ^{[1
]}

Repine, J ^{[1
]}

Bradford, L ^{[1
]}

Reyner, E ^{[1
]}

Stewart, B ^{[1
]}

Hallak, H ^{[1
]}

Welch, KM ^{[1
]}

Walker, D ^{[1
]}

Haleen, S ^{[1
]}

Doherty, A ^{[1
]}

机构：

[1] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,ANN ARBOR,MI 48105

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1997年 / 213卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

页码：195 / MEDI

页数：1

共 50 条

[41] A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow
Ishikawa, A
Suzuki, K
Fujita, K
UROLOGICAL RESEARCH, 1999, 27 (05): : 312 - 314
[42] CONFORMATIONAL STUDY OF CYCLO[D-TRP-D-ASP-PRO-D-VAL-LEU], AN ENDOTHELIN-A RECEPTOR-SELECTIVE ANTAGONIST
ATKINSON, RA
PELTON, JT
FEBS LETTERS, 1992, 296 (01): : 1 - 6
[43] Sitaxsentan, a selective endothelin-A receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD)
Seibold, J
Badesch, D
Galie, N
Langleben, D
Naeije, R
Simonneau, G
Barst, R
CHEST, 2005, 128 (04) : 219S - 219S
[44] A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow
Akira Ishikawa
Kazuo Suzuki
Kimio Fujita
Urological Research, 1999, 27 : 312 - 314
[45] DISCOVERY OF DEGARELIX, A SELF-DEPOTING GnRH ANTAGONIST WITH LONG DURATION OF ACTION
Schteingart, C.
Jiang, G.
Galyean, R.
Stalewski, J.
Rivier, J.
White, R.
Schwach, G.
BIOPOLYMERS, 2009, 92 (04) : 299 - 299
[46] Sitaxsentan, a selective endothelin-A receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD).
Seibold, JR
Langleben, D
Badesch, D
Naeije, E
Simonneau, G
Galie, N
Barst, RJ
ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S282 - S282
[47] 3.: Endothelin antagonists:: Discovery of EMD 122946, a highly potent and orally active ETA selective antagonist
Mederski, WWKR
Dorsch, D
Osswald, M
Anzali, S
Christadler, M
Schmitges, CJ
Schelling, P
Wilm, C
Fluck, M
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (13) : 1771 - 1776
[48] Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ETA receptor antagonist
Yuyama, H
Sanagi, M
Koakutsu, A
Mori, M
Fujimori, A
Harada, H
Sudoh, K
Miyata, K
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 478 (01) : 61 - 71
[49] TBC11251, a highly selective endothelin-A receptor antagonist, prevents and reverses acute hypoxia-induced pulmonary hypertension in the rat.
Chen, SJ
Brock, T
Stavros, F
Okun, I
Wu, C
Chan, F
Mong, S
Dixon, RAF
Oparil, S
Chen, YF
FASEB JOURNAL, 1996, 10 (03): : 601 - 601
[50] Acute effect of a selective endothelin-A receptor antagonist, S-0139, against cyclosporine-induced reduction in renal cortical blood flow
Akira Ishikawa
Kazuo Suzuki
Kimio Fujita
Clinical and Experimental Nephrology, 1997, 1 (4) : 297 - 300

← 1 2 3 4 5 →